Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use
Publication number
US11096969B2
Assignee
LYMPHOGENIX LTD
Application Domain
Pharmaceutical delivery mechanism
Unknown materials
Cardiovascular disorder
Publication Date
24 Aug 2021
Patent Value
$ 3,100,000
Abstract
The present invention aims to provide a method which has not been established yet and which is useful for achieving long-term and fundamental cure of a necrotic cardiac tissue region to allow recovery of functionality of the heart.
The present invention provides an injectable composition for treatment of a cardiac disease, the composition comprising fibroblasts, wherein the fibroblasts contain CD106-positive fibroblasts, preferably contain CD90-positive fibroblasts, and the fibroblasts do not form colonies.
Technical Problem Summary
Current treatments for cardiac diseases, such as heart failure due to myocardial infarction or cardiomyopathy, lack effective methods for long-term recovery of cardiac function, and existing regenerative medicine approaches have not shown significant long-term improvements in heart function.
Benefit Summary
The administration of CD106-positive fibroblasts leads to improved cardiac function, as evidenced by increased left ventricular ejection fraction and fractional shortening, and significant reduction in collagenous fibrotic infarct areas, indicating effective treatment of cardiac diseases.